Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil

Jong Eun Yeon, W. Yoo, S. P. Hong, Y. J. Chang, S. K. Yu, Ji Hoon Kim, Yeon Seok Seo, H. J. Chung, M. S. Moon, S. O. Kim, Kwan Soo Byun, C. H. Lee

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

Background: Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild-type and lamivudine (LMV) resistant hepatitis B virus (HBV). The cumulative incidence of ADV resistant mutations in the nucleoside/-tide treatment naïve chronic hepatitis B patient (CHB) at weeks 48, 96, and 144 was 0, 0.8-3%, and ∼5.9%, respectively. Aims: The aim of this study was to characterise the genotypic and phenotypic mutation profiles to ADV in 67 LMV resistant CHB patients who were treated with ADV. Methods: Serum HBV DNA was quantified by real time polymerase chain reaction. The ADV mutant was detected using matrix assisted laser desorption/ionisation time of flight mass spectrometry based genotyping assays, termed restriction fragment mass polymorphism (RFMP). Results: RFMP analysis revealed that a total of 11 amino acid substitutions developed in the rt domain of the HBV polymerase in nine patients. The cumulative incidence of genotypic ADV resistance at months 12 and 24 was 6.4% and 25.4%, respectively. The rtA181V, rtN236T, and rtA181T mutations were detected in five, four, and two of the 67 patients at treatment months 12-17, 3-19, and 7-20, respectively. Serial quantification of serum HBV DNA revealed that two patients with the rtA181V mutation, with or without the rtN236T mutation, and one patient with the rtA181T mutation displayed HBV DNA rebound. Conclusion: Emergence of the ADV mutation in LMV resistant patients who are treated with ADV appeared to present earlier and more frequently than was reported in previous studies on nucleoside/-tide treatment naïve patients.

Original languageEnglish
Pages (from-to)1488-1495
Number of pages8
JournalGut
Volume55
Issue number10
DOIs
Publication statusPublished - 2006 Oct 1

Fingerprint

Lamivudine
Chronic Hepatitis B
Hepatitis B virus
Mutation
Nucleosides
DNA
adefovir dipivoxil
Incidence
Amino Acid Substitution
Serum
Real-Time Polymerase Chain Reaction
Mass Spectrometry
Lasers
Therapeutics
Nucleotides

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. / Yeon, Jong Eun; Yoo, W.; Hong, S. P.; Chang, Y. J.; Yu, S. K.; Kim, Ji Hoon; Seo, Yeon Seok; Chung, H. J.; Moon, M. S.; Kim, S. O.; Byun, Kwan Soo; Lee, C. H.

In: Gut, Vol. 55, No. 10, 01.10.2006, p. 1488-1495.

Research output: Contribution to journalArticle

Yeon, Jong Eun ; Yoo, W. ; Hong, S. P. ; Chang, Y. J. ; Yu, S. K. ; Kim, Ji Hoon ; Seo, Yeon Seok ; Chung, H. J. ; Moon, M. S. ; Kim, S. O. ; Byun, Kwan Soo ; Lee, C. H. / Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. In: Gut. 2006 ; Vol. 55, No. 10. pp. 1488-1495.
@article{971053eb974d4f58910e11955d8962e2,
title = "Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil",
abstract = "Background: Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild-type and lamivudine (LMV) resistant hepatitis B virus (HBV). The cumulative incidence of ADV resistant mutations in the nucleoside/-tide treatment na{\"i}ve chronic hepatitis B patient (CHB) at weeks 48, 96, and 144 was 0, 0.8-3{\%}, and ∼5.9{\%}, respectively. Aims: The aim of this study was to characterise the genotypic and phenotypic mutation profiles to ADV in 67 LMV resistant CHB patients who were treated with ADV. Methods: Serum HBV DNA was quantified by real time polymerase chain reaction. The ADV mutant was detected using matrix assisted laser desorption/ionisation time of flight mass spectrometry based genotyping assays, termed restriction fragment mass polymorphism (RFMP). Results: RFMP analysis revealed that a total of 11 amino acid substitutions developed in the rt domain of the HBV polymerase in nine patients. The cumulative incidence of genotypic ADV resistance at months 12 and 24 was 6.4{\%} and 25.4{\%}, respectively. The rtA181V, rtN236T, and rtA181T mutations were detected in five, four, and two of the 67 patients at treatment months 12-17, 3-19, and 7-20, respectively. Serial quantification of serum HBV DNA revealed that two patients with the rtA181V mutation, with or without the rtN236T mutation, and one patient with the rtA181T mutation displayed HBV DNA rebound. Conclusion: Emergence of the ADV mutation in LMV resistant patients who are treated with ADV appeared to present earlier and more frequently than was reported in previous studies on nucleoside/-tide treatment na{\"i}ve patients.",
author = "Yeon, {Jong Eun} and W. Yoo and Hong, {S. P.} and Chang, {Y. J.} and Yu, {S. K.} and Kim, {Ji Hoon} and Seo, {Yeon Seok} and Chung, {H. J.} and Moon, {M. S.} and Kim, {S. O.} and Byun, {Kwan Soo} and Lee, {C. H.}",
year = "2006",
month = "10",
day = "1",
doi = "10.1136/gut.2005.077099",
language = "English",
volume = "55",
pages = "1488--1495",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "10",

}

TY - JOUR

T1 - Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil

AU - Yeon, Jong Eun

AU - Yoo, W.

AU - Hong, S. P.

AU - Chang, Y. J.

AU - Yu, S. K.

AU - Kim, Ji Hoon

AU - Seo, Yeon Seok

AU - Chung, H. J.

AU - Moon, M. S.

AU - Kim, S. O.

AU - Byun, Kwan Soo

AU - Lee, C. H.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Background: Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild-type and lamivudine (LMV) resistant hepatitis B virus (HBV). The cumulative incidence of ADV resistant mutations in the nucleoside/-tide treatment naïve chronic hepatitis B patient (CHB) at weeks 48, 96, and 144 was 0, 0.8-3%, and ∼5.9%, respectively. Aims: The aim of this study was to characterise the genotypic and phenotypic mutation profiles to ADV in 67 LMV resistant CHB patients who were treated with ADV. Methods: Serum HBV DNA was quantified by real time polymerase chain reaction. The ADV mutant was detected using matrix assisted laser desorption/ionisation time of flight mass spectrometry based genotyping assays, termed restriction fragment mass polymorphism (RFMP). Results: RFMP analysis revealed that a total of 11 amino acid substitutions developed in the rt domain of the HBV polymerase in nine patients. The cumulative incidence of genotypic ADV resistance at months 12 and 24 was 6.4% and 25.4%, respectively. The rtA181V, rtN236T, and rtA181T mutations were detected in five, four, and two of the 67 patients at treatment months 12-17, 3-19, and 7-20, respectively. Serial quantification of serum HBV DNA revealed that two patients with the rtA181V mutation, with or without the rtN236T mutation, and one patient with the rtA181T mutation displayed HBV DNA rebound. Conclusion: Emergence of the ADV mutation in LMV resistant patients who are treated with ADV appeared to present earlier and more frequently than was reported in previous studies on nucleoside/-tide treatment naïve patients.

AB - Background: Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild-type and lamivudine (LMV) resistant hepatitis B virus (HBV). The cumulative incidence of ADV resistant mutations in the nucleoside/-tide treatment naïve chronic hepatitis B patient (CHB) at weeks 48, 96, and 144 was 0, 0.8-3%, and ∼5.9%, respectively. Aims: The aim of this study was to characterise the genotypic and phenotypic mutation profiles to ADV in 67 LMV resistant CHB patients who were treated with ADV. Methods: Serum HBV DNA was quantified by real time polymerase chain reaction. The ADV mutant was detected using matrix assisted laser desorption/ionisation time of flight mass spectrometry based genotyping assays, termed restriction fragment mass polymorphism (RFMP). Results: RFMP analysis revealed that a total of 11 amino acid substitutions developed in the rt domain of the HBV polymerase in nine patients. The cumulative incidence of genotypic ADV resistance at months 12 and 24 was 6.4% and 25.4%, respectively. The rtA181V, rtN236T, and rtA181T mutations were detected in five, four, and two of the 67 patients at treatment months 12-17, 3-19, and 7-20, respectively. Serial quantification of serum HBV DNA revealed that two patients with the rtA181V mutation, with or without the rtN236T mutation, and one patient with the rtA181T mutation displayed HBV DNA rebound. Conclusion: Emergence of the ADV mutation in LMV resistant patients who are treated with ADV appeared to present earlier and more frequently than was reported in previous studies on nucleoside/-tide treatment naïve patients.

UR - http://www.scopus.com/inward/record.url?scp=33749170143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749170143&partnerID=8YFLogxK

U2 - 10.1136/gut.2005.077099

DO - 10.1136/gut.2005.077099

M3 - Article

C2 - 16461777

AN - SCOPUS:33749170143

VL - 55

SP - 1488

EP - 1495

JO - Gut

JF - Gut

SN - 0017-5749

IS - 10

ER -